KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2016 - 2025)

Jazz Pharmaceuticals has reported Other Operating Expenses over the past 16 years, most recently at $323.3 million for Q4 2025.

  • Quarterly Other Operating Expenses rose 12.4% to $323.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, up 70.52% year-over-year, with the annual reading at $2.1 billion for FY2025, 94.44% up from the prior year.
  • Other Operating Expenses was $323.3 million for Q4 2025 at Jazz Pharmaceuticals, down from $339.7 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $1.2 billion in Q2 2025 and troughed at $108.4 million in Q1 2021.
  • The 5-year median for Other Operating Expenses is $287.4 million (2022), against an average of $351.4 million.
  • Biggest five-year swings in Other Operating Expenses: tumbled 74.79% in 2021 and later skyrocketed 346.48% in 2025.
  • Tracing JAZZ's Other Operating Expenses over 5 years: stood at $293.4 million in 2021, then surged by 131.64% to $679.8 million in 2022, then plummeted by 59.28% to $276.8 million in 2023, then rose by 3.91% to $287.6 million in 2024, then grew by 12.4% to $323.3 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $323.3 million, $339.7 million, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.